Sino-Singapore Jingwei, July 25th. On the evening of the 25th, Fosun Pharma announced that its holding subsidiary Fosun Pharma Industry signed a “Strategic Cooperation Agreement” with Real Biology, to promote the joint development of the two parties and that Fosun Pharma Industry The exclusive commercialization of Azvudine and other matters reached a strategic cooperation.
According to public information, Fosun Pharma is a global pharmaceutical and health industry group with direct operations including pharmaceuticals, medical devices and medical diagnosis, and medical and health services.
The announcement shows that in this cooperation, the two parties will jointly develop cooperative products, and Fosun Pharmaceutical Industry enjoys the exclusive commercialization rights of the cooperative products. Commercialization includes distribution, import, export, sales, and promotion. At the same time, Fosun Pharma can re-license the rights under this cooperation to its affiliates or non-affiliated third parties according to the contract.
The areas of cooperation between the two parties are all fields related to the treatment and prevention of the new coronavirus with Azvudine; all fields related to the treatment and prevention of AIDS with Azvudine. In the field of cooperation, the cooperative products include azvudine APIs, tablets, and all other dosage forms containing azvudine API ingredients, but do not include excluded products (i.e., the drugs being developed by Real Bio for the treatment of AIDS, Combination product consisting of Azvudine and a real biological newly developed molecule).
It is worth noting that just before the above announcement was issued, the State Food and Drug Administration just conducted emergency review and approval in accordance with the relevant provisions of the “Drug Administration Law” and in accordance with the special drug approval procedures, and approved Henan with conditions. Real Biotechnology Co., Ltd. added Azvudine Tablets for registration applications for the treatment of new coronavirus pneumonia.
It is reported that Azvudine Tablets is an oral small molecule drug independently developed by my country. As a broad-spectrum RNA virus inhibitor, it can inhibit the new coronavirus RNA-dependent RNA polymerase (RdRp). (Sino-Singapore Jingwei APP)